The Prevention of Contrast Induced Nephropathy by Sarpogrelate in Patients With Chronic Kidney Disease
Status:
Unknown status
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
Background:
Contrast-induced nephropathy (CIN) is a serious clinical problem associated with increased
morbidity and mortality, particularly in patients with chronic renal insufficiency. Although
some agents including hydration with saline are being prescribed to prevent renal
deterioration in these high risk patients, their efficacy is not clear defined and debatable.
Therefore additional prophylactic pretreatments are needed.
Methods/Design:
Present study aims to investigate differences in occurrence of CIN after sarpogrelate
premedication in patients with chronic kidney disease (CKD). 268 participants, aged 20-85
years with a clinical diagnosis of CKD will be recruited. They will be randomly allocated to
one of two conditions: (i) a routine treatment without sarpogrelate group (ii) routine
treatment with sarpogrelate (a fixed-flexible dose of 300 mg/day). The primary outcome is the
occurrence of CIN during 4 weeks after receiving contrast agent.
Discussion:
As of May 2010, there were no registered trials evaluating the therapeutic potentials of
sarpogrelate in preventing for CIN. If sarpogrelate decreases the worsening of renal function
and occurrence of CIN, it will provide a safe, easy and inexpensive treatment option.